Oruka Therapeutics, Inc.
ORKA
Rankning i aktier
#3273
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Aktiekurs
$81.06
Marknadsvärde
$5.37B
Förändring (1 dag)
1.43%
Förändring (1 år)
204.17%
Land
US
Handel Oruka Therapeutics, Inc. (ORKA)
Kategori
Healthcare
Aktiekurshistorik för Oruka Therapeutics, Inc. (ORKA)
Högsta slutkurs: $79.19 den 2026-10-01
Lägsta slutkurs: $4.84M den 1997-12-01
Lägsta slutkurs: $4.84M den 1997-12-01
Aktiekurshistorik för Oruka Therapeutics, Inc. från 1997 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 94.71% |
| 2025 | 42.90% |
| 2024 | -0.16% |
| 2023 | -22.61% |
| 2022 | -0.72% |
| 2021 | -45.08% |
| 2020 | -24.36% |
| 2019 | -28.32% |
| 2018 | -68.07% |
| 2017 | -46.86% |
| 2016 | -51.59% |
| 2015 | -15.86% |
| 2014 | -43.56% |
| 2013 | -26.26% |
| 2012 | -71.67% |
| 2011 | -61.96% |
| 2010 | 8.83% |
| 2009 | -51.11% |
| 2008 | -84.91% |
| 2007 | -76.28% |
| 2006 | 3.31% |
| 2005 | -17.12% |
| 2004 | -4.50% |
| 2003 | 257.05% |
| 2002 | -86.09% |
| 2001 | -11.58% |
| 1999 | 76.44% |
| 1998 | -48.78% |
| 1997 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $536.71 | 25.86% |
US
|
|
| $192.49 | 616.91% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $883.40 | 8.50% |
NL
|
